Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
BETA v.3.0

2025 ICD-10-CM code O28.1

Abnormal biochemical finding on antenatal screening of mother.

This code should be used only on the maternal record, not the newborn's record.It is applicable when an abnormal biochemical finding is identified during antenatal screening.Do not use this code for abnormal findings unrelated to pregnancy or if a definitive diagnosis has been established. An additional code from category Z3A, Weeks of gestation, should be used to identify the specific week of the pregnancy, if known.

Medical necessity for antenatal biochemical screening is based on established guidelines and risk factors for various pregnancy complications.These guidelines take into account maternal age, family history, and other relevant factors.Documentation should clearly support the medical necessity for the specific tests performed and any subsequent diagnostic procedures.

Obstetricians, maternal-fetal medicine specialists, and other healthcare professionals involved in antenatal care are responsible for interpreting the results of biochemical screenings and recommending appropriate follow-up actions. These actions may include further diagnostic testing, counseling, or referral to specialists.

In simple words: During routine pregnancy blood tests, something unusual was found. This doesn't automatically mean there's a problem, but it warrants further investigation.

This code signifies an abnormal biochemical finding discovered during the antenatal screening of the mother.Antenatal screening involves various tests performed during pregnancy to assess the health of both the mother and the developing fetus.Biochemical tests analyze substances in the mother's blood or urine, such as alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and estriol.Abnormal levels of these substances can indicate potential risks or complications, such as Down syndrome, neural tube defects, or other fetal abnormalities.

Example 1: A pregnant woman in her first trimester undergoes a combined first-trimester screening, which includes a biochemical test.The results show an elevated level of hCG and a low level of PAPP-A (pregnancy-associated plasma protein A), raising concerns about Down syndrome. Additional diagnostic testing, such as chorionic villus sampling or amniocentesis, may be recommended to confirm the diagnosis., During a routine antenatal visit in the second trimester, a pregnant woman's blood test reveals an elevated level of AFP.This finding could indicate a neural tube defect in the fetus. An ultrasound and further diagnostic tests are performed to evaluate the fetus's spine and brain for abnormalities., A pregnant woman's urine sample shows an abnormally low level of estriol during a third-trimester checkup. This finding may indicate placental insufficiency or fetal growth restriction.Further monitoring and management may be necessary to ensure the health of the fetus.

Documentation should include the specific biochemical test performed, the results of the test, the gestational age at the time of testing, and any associated diagnostic or imaging findings. Any recommendations for further testing or consultation should also be documented. Any patient education and counseling provided should be noted, along with informed consent for further testing, if applicable.

** It is essential to differentiate between screening tests and diagnostic tests. Screening tests assess risk, while diagnostic tests confirm or rule out specific conditions. An abnormal screening result does not necessarily indicate a problem but warrants further investigation.

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.